The US Bureau of Labor Statistics will release the September nonfarm payrolls report, with Wall Street expecting a job growth of 84,000 and the unemployment rate steady at 4.1%. This reflects a stable labor market after a strong August gain and aligns with Federal Reserve officials' views that the labor market is solid but inflation remains the main concern. Wage growth has moderated, and layoffs remain low, though worker confidence is at record lows amid economic uncertainties and fears around AI. The Fed is likely to hold off on a rate hike in October, focusing instead on inflation, with a possible move expected in December.
The September jobs report is due Friday, with Wall Street expecting 84,000 new jobs and unemployment steady at 4.1%. For readers following US stocks on Pluang, here is the market snapshot as of Oct 02, 2026 01:21 WIB: out of 150 priced stocks, 76 rose and 73 fell. Notable movers include AMC at USD 2.74 with a 1-day change of -8.67%, Unity Software at USD 43.22 up 5.59%, and Occidental Petroleum at USD 57.48 up 3.90%.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
